STUDYING THE RENAL ADVERSE EFFECTS IN SPONDYLOARTHRITIS SUBJECTS ON NON STEROIDAL ANTI STEROIDAL DRUGS

Abstract

Background: NSAIDs are the primary treatment for spondyloarthritis, which is primarily diagnosed and treated by evaluating radiological findings, laboratory results, symptoms, and history. Subclinical renal damage, on the other hand, may result from them and go undetected on tests like creatinine. 

Aim: Using serum cystatin-c and serum creatinine as benchmarks, investigate the relationship between the length of NSAID usage and the occurrence of subclinical renal damage in individuals with spondyloarthritis. Methods: This prospective observational research, which is hospital-based, was conducted on 36 individuals who suffer from spondyloarthritis. At baseline, 4 weeks, and 12 weeks, the blood creatinine and cystatin-c levels were measured. The gathered data were evaluated in order to formulate the results.

Results: After 12 weeks, there was no significant difference in the participants with spondyloarthritis who used various NSAIDs in terms of serum creatinine (p=0.548). However, there was a significant difference in the serum cystatin C levels (p<0.001) after 12 weeks.

Conclusion: There was no discernible change in the blood creatinine levels after taking NSAIDs. In contrast to serum creatinine, cystatin-c can be utilised as an early biomarker for subclinical renal impairment because there was a notable two- or three-fold rise in blood levels seen compared to the baseline value.